-
Mashup Score: 0Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer - 2 year(s) ago
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 vaccines, neutralising antibody (nAb) responses against the B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta) variants of concern (VOCs) are decreased compared to the wild type (WT) SARS-CoV-2, particularly in…
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer - 2 year(s) ago
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 vaccines, neutralising antibody (nAb) responses against the B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta) variants of concern (VOCs) are decreased compared to the wild type (WT) SARS-CoV-2, particularly in…
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
Omicron neutralising antibodies after 3rd #COVID19Vaccine dose in Pts w/ cancer [Jan 25, 2022] @fendler_annika et al. @TurajlicLab on behalf of the CAPTURE consortium #CAPTUREStudy @TheLancet https://t.co/anJ0ef59Le #COVID19nCancer #IDonc @TheCrick @royalmarsdenNHS
-
-
Mashup Score: 4Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer - 2 year(s) ago
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 vaccines, neutralising antibody (nAb) responses against the B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta) variants of concern (VOCs) are decreased compared to the wild type (WT) SARS-CoV-2, particularly in…
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Patients with cancer are at greater risk of severe #COVID19. In a research letter, @fendler_annika & colleagues evaluate neutralising antibody responses against #omicron following 3 doses of COVID-19 vaccine in patients with cancer. #CAPTUREStudy https://t.co/tTKHZQVxPV
-
-
Mashup Score: 3Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer - 2 year(s) ago
Patients with cancer are at greater risk of severe COVID-19 and have been prioritised for COVID-19 vaccination globally. We previously showed that following two doses of COVID-19 vaccines, neutralising antibody (nAb) responses against the B.1.1.7 (alpha), B.1.351 (beta), and B.1.617.2 (delta) variants of concern (VOCs) are decreased compared to the wild type (WT) SARS-CoV-2, particularly in…
Source: The LancetCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer: a research letter from @fendler_annika & colleagues. #CAPTUREStudy https://t.co/GxwjvJ0EzD
-
-
Mashup Score: 25
Turajlic and colleagues assess longitudinal antibody and cellular immune responses against SARS-CoV-2 variants of concern in patients with cancer, following either recovery from SARS-CoV-2 infection or vaccination, in two back-to-back reports from the CAPTURE study.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
š„š„ONLINE @NatureCancer, two papers from the #CAPTUREstudy - Functional antibody & T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with #cancer -- a *FAB* set by @TurajlicLab &Co (1/2) DO NOT MISSā¼ļø https://t.co/YRl4TtVeqM #COVID19 https://t.co/9vk8Dkg8xT
-
-
Mashup Score: 6
Turajlic and colleagues assess longitudinal antibody and cellular immune responses against SARS-CoV-2 variants of concern in patients with cancer, following either recovery from SARS-CoV-2 infection or vaccination, in two back-to-back reports from the CAPTURE study.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
š„š„ONLINE NOW @NatureCancer, two papers from the #CAPTUREstudy - Adaptive immunity & neutralizing antibodies against SARS-CoV-2 variants of concern following #vaccination in patients with cancer - also by @TurajlicLab &Co (2/2) FIND IT HEREā¼ļø https://t.co/BEISVNkFVY #COVID19 https://t.co/fSGusD41Cm
-
Omicron neutralising antibodies after 3rd #COVID19Vaccine dose in Pts w/ cancer [Jan 25, 2022] @fendler_annika et al. @TurajlicLab on behalf of the CAPTURE consortium #CAPTUREStudy @TheLancet https://t.co/anJ0ef59Le #COVID19nCancer #IDonc @TheCrick @royalmarsdenNHS